MTD is the abbreviation for methadone on a drug screen. When you see “MTD” listed on a urine drug test panel or results report, the lab is checking specifically for methadone or its metabolites. Unlike many other opioids, methadone does not trigger the standard “OPI” (opiates) line on a drug screen, so it requires its own dedicated test. Understanding what a positive or negative MTD result actually means, and what can throw it off, takes more nuance than most people expect.
Why Methadone Gets Its Own Line on the Panel
Standard opiate immunoassays are designed to detect drugs structurally similar to morphine, which includes heroin, codeine, and sometimes hydrocodone or hydromorphone depending on the assay. Methadone is a synthetic opioid with a different chemical structure, so it slips past those tests entirely. A person could be taking methadone daily and still show a clean result on the OPI line. That is why drug panels that need to detect methadone include MTD as a separate target.
Methadone is prescribed in two very different contexts. It is a long-acting medication used in opioid-dependence treatment programs, where it reduces cravings and blocks withdrawal symptoms, and it is also prescribed for chronic pain management at lower doses.1PubMed Central. Optimum methadone compliance testing: an evidence-based analysis In addiction treatment, regular urine drug screens verify that a patient is actually taking their prescribed methadone and not diverting it (selling or giving it away). In pain management, the same test helps confirm adherence. In workplace or forensic settings, the goal flips: the screen checks whether someone is using methadone without a prescription. The interpretation of your result depends heavily on which of these situations applies to you.
How MTD Screening Works
Most initial drug screens use immunoassay technology, where antibodies in a test reagent bind to methadone or its metabolites in your urine sample. If the concentration exceeds a preset cutoff, typically 300 ng/mL, the result is reported as positive. This initial screen is fast and inexpensive, but it is not definitive. Immunoassays are designed to cast a wide net, catching most true positives at the cost of occasionally flagging substances that are not actually methadone.
When an initial screen comes back positive, a confirmatory test is usually run. The gold standard for confirmation is a technique called liquid chromatography-tandem mass spectrometry, often abbreviated LC-MS/MS. This method physically separates and identifies the molecules in your sample, so it can distinguish methadone from a chemically unrelated drug that happened to trigger the immunoassay antibodies. A confirmed positive means methadone (or its metabolite EDDP) was genuinely present at a measurable level. A screen positive that fails confirmation is reclassified as a false positive.
How often false positives happen depends on which immunoassay platform the lab uses. A 2024 comparison of two widely used platforms found strikingly different performance. One assay (the Architect platform) had a false-positive rate of about 5%, meaning roughly 95% of its positive screens were confirmed by mass spectrometry. The other (the Roche platform) had a false-positive rate above 30%, with nearly a third of its positive screens turning out to be something other than methadone on confirmatory testing.2Journal of Analytical Toxicology. Comparative performance of methadone urine immunoassays based on real-world data reveals assay interference That is an enormous gap and highlights why a positive screen alone should never be treated as a final answer.
Common Causes of False-Positive MTD Results
If you have never taken methadone and your drug screen comes back positive for MTD, a medication you are taking could be to blame. The most frequently reported culprit is quetiapine, an antipsychotic sold under the brand name Seroquel. In one hospital review, every single false-positive methadone screen over an 18-month period occurred in a patient taking quetiapine, and researchers estimated that serum quetiapine levels as low as about 60 ng/mL could be enough to trigger the false result.3The Journal of Clinical Psychiatry. False-Positive Methadone Drug Screens During Quetiapine Treatment Doses as low as 125 mg per day of quetiapine have been sufficient to do it in some patients.
Vortioxetine, an antidepressant marketed as Trintellix, has also been identified as a cross-reactant on certain methadone immunoassay platforms. In the real-world comparison study mentioned earlier, medication reviews of false-positive Roche results frequently turned up quetiapine and vortioxetine.2Journal of Analytical Toxicology. Comparative performance of methadone urine immunoassays based on real-world data reveals assay interference Other medications have been flagged in isolated case reports over the years, including diphenhydramine (Benadryl) at high doses and certain antidepressants, but quetiapine and vortioxetine are the most consistently documented offenders in clinical data.
If you suspect a false positive, the practical step is straightforward: request confirmatory testing by mass spectrometry. Confirmatory testing will either clear you or confirm true methadone exposure, and many labs will automatically reflex to confirmation when the initial screen is positive. If yours does not, you can ask your provider or the testing authority to order it.
Why a Negative Result Does Not Always Mean No Methadone
False negatives on the MTD line are less discussed but equally real. A person who is genuinely taking methadone can produce a negative screen for several reasons. The most common is simply timing and dilution. If you drank large amounts of fluid before the test, the methadone concentration in your urine may fall below the assay’s cutoff even though the drug is in your system. Immunoassays have a built-in threshold, and anything below it reads as negative regardless of whether the drug is technically present.4Bioanalysis. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing
Other causes of false negatives include the limited specificity of some assays and, in rare cases, laboratory error. Specimen manipulation, whether through dilution, substitution, or chemical adulteration, is another recognized cause. Labs counter this with specimen-validity testing that checks urine temperature, pH, creatinine concentration, and specific gravity. A sample that looks too dilute or chemically abnormal gets flagged, and you may be asked to retest under direct observation.
The EDDP Test and What It Reveals
Some drug screens test not just for methadone itself but for EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine), which is methadone’s primary metabolite. EDDP is produced when your liver processes methadone, so its presence in urine is strong evidence that you actually ingested and metabolized the drug, rather than simply adding liquid methadone to a urine sample after collection.
This distinction matters in compliance monitoring. In one study evaluating the EDDP immunoassay, seven urine specimens tested negative for EDDP and were confirmed negative by a more precise lab method, yet contained methadone at concentrations ranging from 4,000 to 37,500 micrograms per liter. The researchers concluded these samples had been “spiked,” meaning the patient had poured methadone directly into the urine cup to simulate compliance rather than swallowing the dose.5PubMed. Application and validation of a urinary methadone metabolite (EDDP) immunoassay to monitor methadone compliance High methadone with absent EDDP is a red flag that the drug was never actually metabolized.
That said, a methadone-positive but EDDP-negative result does not automatically prove tampering. Urinary pH plays a role: when urine is more alkaline, less methadone is excreted by the kidneys, and the ratio of methadone to EDDP shifts. A study of urine samples from Norwegian prisons concluded that methadone-positive, EDDP-negative results may suggest sample tampering in some but not all cases, because pH-driven variation in methadone excretion can produce the same pattern legitimately.6PubMed. Relationship between methadone and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) in urine samples from Norwegian prisons
How Urinary pH Changes Your Results
Your urine’s acidity or alkalinity has a surprisingly large influence on how much methadone shows up in a drug screen. Methadone is a weak base, which means it dissolves more readily into acidic urine. When urine pH drops below about 6 (acidic), the kidneys excrete substantially more methadone, and the drug’s plasma half-life shortens considerably. In a study that manipulated urine pH using ammonium chloride (to acidify) and sodium bicarbonate (to alkalinize) in the same group of subjects, the plasma half-life of methadone was roughly 19 hours with acidic urine versus about 42 hours with alkaline urine.7PubMed. Clinical pharmacokinetics of methadone That is more than a twofold difference driven purely by urine chemistry.
In practical terms, a person with more acidic urine (from diet, medications, or natural variation) will excrete more methadone into each urine sample, making a positive screen more likely even at lower doses. A person with more alkaline urine will retain more methadone in the bloodstream and excrete less into urine, potentially producing a weaker signal or even a false negative on an immunoassay. This is one reason clinicians should not interpret a single negative methadone screen as proof of non-compliance without considering the patient’s hydration status and urine pH.
Genetics and Drug Interactions That Alter Methadone Metabolism
How quickly your body breaks down methadone is partly determined by your genetics. Methadone is metabolized by several liver enzymes, and variations in the genes coding for these enzymes can meaningfully change how much methadone ends up in your blood and urine. The best-studied genetic factor involves the CYP2B6 enzyme. People who carry certain variants of the CYP2B6 gene (particularly those homozygous for the *6 allele) metabolize methadone more slowly, leading to higher blood concentrations and slower clearance. On the other hand, carriers of the CYP2B6*4 variant break methadone down faster, resulting in lower concentrations.8PubMed Central. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance and metabolism
Beyond CYP2B6, genetic variation in CYP3A4 and CYP2D6 enzymes can also affect methadone levels in the body.9PubMed. Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review On top of genetics, other medications you take can speed up or slow down these same enzymes. Drugs that induce CYP3A4 activity, such as rifampin (used for tuberculosis) and certain anti-seizure medications like carbamazepine, can accelerate methadone breakdown, potentially pushing urine levels below the test cutoff and causing an unexpected negative. Conversely, drugs that inhibit these enzymes, such as certain antifungals and some HIV medications, slow methadone metabolism and can cause higher-than-expected urine concentrations.
None of this means you need genetic testing before interpreting a drug screen, but it helps explain why two people on the same methadone dose can produce very different urine results. If your results seem inconsistent with your prescribed dose, enzyme-related variation is one legitimate explanation worth raising with your prescriber.
Point-of-Care Cups Versus Lab-Based Screens
Not all drug screens are processed in a central laboratory. Many clinics, emergency rooms, and workplace testing programs use point-of-care (POC) testing cups that give a visual positive or negative result in minutes, much like a home pregnancy test. These cups are convenient but come with performance trade-offs.
An evaluation of two commercial POC cup products (NexScreen and DrugCheck Waive RT) found different accuracy profiles when results were compared against mass spectrometry confirmation. The NexScreen cups produced false positives for several drug classes including methadone, meaning they flagged samples that did not actually contain the drug. The DrugCheck cups, meanwhile, had no false positives for methadone but did produce false negatives for some other drug classes.10Journal of Analytical Toxicology. Evaluation of the NexScreen and DrugCheck Waive RT Urine Drug Detection Cups The takeaway is that point-of-care results are preliminary. A positive MTD reading from a rapid cup warrants the same confirmatory testing you would expect from a lab immunoassay. If a treatment or employment decision rests on the result, do not let a rapid cup be the last word.
Methadone Screening in Pregnancy and Neonatal Care
Methadone testing takes on additional dimensions during pregnancy. Women receiving methadone as part of medication-assisted treatment for opioid use disorder are often screened at delivery, and the results help guide neonatal care. Babies born to mothers on methadone are at risk for neonatal opioid withdrawal syndrome (sometimes called NOWS), which can require monitoring and treatment in the hospital.
Some hospitals test the umbilical cord tissue in addition to maternal urine at delivery. Research has explored whether cord testing adds useful information beyond what the maternal urine screen provides in predicting which infants will develop withdrawal symptoms and how severe those symptoms will be.11PubMed. Can umbilical cord testing add to maternal urine drug screen for evaluation of infants at risk of neonatal opioid withdrawal syndrome? The maternal urine screen tells you what was in the mother’s system around the time of delivery, while cord tissue can detect substances the baby was exposed to over a longer window. For mothers prescribed methadone, a positive maternal screen is expected and not a cause for alarm on its own; the clinical team uses the information to prepare appropriate monitoring for the newborn.
What to Do When Your MTD Result Does Not Make Sense
If you are prescribed methadone and your test comes back negative, consider whether you were well-hydrated before the test, whether your urine pH may have been unusually alkaline, and whether any of your other medications could be interacting with methadone metabolism. A single negative screen does not necessarily mean the drug was not in your system. If your prescriber is concerned about compliance, a follow-up test with measured urine creatinine and pH can help sort out whether dilution or chemistry explains the result.
If you are not taking methadone and your screen came back positive, the most important thing is to ensure confirmatory testing is performed. Given that some immunoassay platforms have false-positive rates above 30%, an unconfirmed positive screen by itself is unreliable. Medications like quetiapine and vortioxetine are well-documented causes of false-positive MTD results, and if you are taking either of these, let the medical review officer or testing authority know. Confirmation by mass spectrometry will settle the question. In employment or legal contexts, you have the right to request confirmatory testing, and any responsible testing program should offer it before taking adverse action based on a screening result alone.
The abbreviation “MTD” on a report is just one data point. The number beside it (if quantitative), the presence or absence of the EDDP metabolite, the specimen-validity indicators, and your medication history all matter for interpreting what that three-letter code actually means for you.